{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.6","upperLimit":"48.1","value":"29.1"},{"groupId":"OG001","lowerLimit":"12.7","upperLimit":"48.0","value":"26.9"},{"groupId":"OG002","lowerLimit":"12.4","upperLimit":"47.4","value":"24.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"62"}],"units":"Participants"}],"description":"n is the number of patients achieving response criteria. The weeks correspond to duration of first response (in weeks) for patients achieving biomedical control. Median and 95% CI are derived from Kaplan-Meier curves. Kaplan-Meier estimates \\[95% CI\\] at each time point are estimates of probability of response.","dispersionType":"95% Confidence Interval","groups":[{"description":"If controlled on 40 mg in CORE, remain on blinded 40 mg in extension. If patient became uncontrolled, switch to open label 60 mg","id":"OG000","title":"Pasireotide LAR 40 mg Extension"},{"description":"If controlled on 60 mg in CORE, remain on blinded 60 mg in extension. If patient became uncontrolled, switch to open label 60 mg","id":"OG001","title":"Pasireotide LAR 60 mg Extension"},{"description":"Open - label 60 mg pasireotide. Control group from CORE discontinued study if controlled in CORE. If uncontrolled in CORE, switched to open label 60 mg pasireotide. Extension blinded 40 and 60 mg switched to open label if became uncontrolled.","id":"OG002","title":"Cross Over to Pasireotide Extension"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"CORE baseline up to approximately 268 weeks","title":"Duration of the First Response for Patients Achieving a Reduction of Mean GH Level to < 2.5 μg/L and Normalization of IGF-1 and Treated With Pasireotide LAR Alone or With Concomitant Medications Used to Treat Acromegaly (Extension Full Analysis Set)","type":"SECONDARY","unitOfMeasure":"weeks"}